自减毒疫苗引入以来脊髓灰质炎病毒的演变
Evolution of poliovirus since introduction of attenuated vaccine.
作者信息
Cossart Y E
出版信息
Br Med J. 1977 Jun 25;1(6077):1621-3. doi: 10.1136/bmj.1.6077.1621.
Abstract
Genetic marker tests were performed on 997 strains of poliovirus isolated from patients with neurological disease and from healthy people in England and Wales. Before the introduction of live attenuated vaccine most strains could multiply at raised temperatures. Now, however, many strains isolated from cases of poliomyelitis or from healthy persons with no known contact with vaccine cannot grow above 37 degrees C, and in this respect resemble the vaccine strains. The three serotypes are also much more evenly represented. Hence probably to a limited extent the vaccine-like strains have established themselves in the community.
摘要
对从英格兰和威尔士患有神经系统疾病的患者以及健康人身上分离出的997株脊髓灰质炎病毒进行了基因标记测试。在减毒活疫苗引入之前，大多数毒株能在较高温度下繁殖。然而现在，许多从脊髓灰质炎病例或与疫苗无已知接触的健康人身上分离出的毒株在37摄氏度以上无法生长，在这方面它们与疫苗毒株相似。三种血清型的分布也更加均匀。因此，类似疫苗的毒株可能在一定程度上已在社区中立足。
相似文献
1
Evolution of poliovirus since introduction of attenuated vaccine.自减毒疫苗引入以来脊髓灰质炎病毒的演变
Br Med J. 1977 Jun 25;1(6077):1621-3. doi: 10.1136/bmj.1.6077.1621.
2
3
Markers of poliovirus strains isolated from cases temporally associated with the use of live poliovirus vaccine: report on a W.H.O. collaborative study.从与使用口服脊髓灰质炎活疫苗存在时间关联的病例中分离出的脊髓灰质炎病毒株标志物：世界卫生组织协作研究报告
J Biol Stand. 1981;9(2):163-84. doi: 10.1016/s0092-1157(81)80021-2.
4
[Prevention of poliomyelitis: live or killed vaccine? Remarks apropos of 2 cases of poliomyelitis].[脊髓灰质炎的预防：活疫苗还是灭活疫苗？关于2例脊髓灰质炎病例的评论]
Presse Med. 1984 Oct 20;13(37):2241-3.
5
Evolution of poliovirus since introduction of attenuated vaccine.自减毒活疫苗引入以来脊髓灰质炎病毒的演变
Br Med J. 1977 Aug 20;2(6085):518. doi: 10.1136/bmj.2.6085.518-b.
6
Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication.三种血清型基因稳定的减毒活脊髓灰质炎病毒疫苗的合理设计：与根除脊髓灰质炎的相关性
J Virol. 2006 Sep;80(17):8653-63. doi: 10.1128/JVI.00370-06.
7
An Introduction to Poliovirus: Pathogenesis, Vaccination, and the Endgame for Global Eradication.脊髓灰质炎病毒简介：发病机制、疫苗接种及全球根除的最终目标
Methods Mol Biol. 2016;1387:1-10. doi: 10.1007/978-1-4939-3292-4_1.
8
Rapid and accurate identification of poliovirus strains used for vaccine production.快速准确地鉴定用于疫苗生产的脊灰病毒株。
J Virol Methods. 2013 Apr;189(1):189-95. doi: 10.1016/j.jviromet.2013.01.026. Epub 2013 Feb 19.
9
Update on Vaccine-Derived Polioviruses - Worldwide, January 2016-June 2017.疫苗衍生脊髓灰质炎病毒最新情况 - 全球，2016年1月至2017年6月
MMWR Morb Mortal Wkly Rep. 2017 Nov 3;66(43):1185-1191. doi: 10.15585/mmwr.mm6643a6.
10
Letter: Poliomyelitis after contact with recently vaccinated infant.信件：与近期接种疫苗的婴儿接触后发生的脊髓灰质炎
Br Med J. 1974 Apr 6;2(5909):53. doi: 10.1136/bmj.2.5909.53.
引用本文的文献
1
Assessing the Risk of Vaccine-derived Outbreaks After Reintroduction of Oral Poliovirus Vaccine in Postcessation Settings.评估停用口服脊髓灰质炎疫苗后重新引入疫苗衍生病毒爆发的风险。
Clin Infect Dis. 2018 Oct 30;67(suppl_1):S26-S34. doi: 10.1093/cid/ciy605.
2
Fetal damage after accidental polio vaccination of an immune mother.免疫母亲意外接种脊髓灰质炎疫苗后对胎儿的损害。
J R Coll Gen Pract. 1984 Jul;34(264):390-4.
3
Molecular cloning of the genomes of poliovirus type 3 strains by the cDNA: RNA hybrid method.通过cDNA:RNA杂交法对3型脊髓灰质炎病毒株基因组进行分子克隆
Arch Virol. 1984;81(1-2):67-78. doi: 10.1007/BF01309297.
4
Comparison of the complete nucleotide sequences of the genomes of the neurovirulent poliovirus P3/Leon/37 and its attenuated Sabin vaccine derivative P3/Leon 12a1b.神经毒性脊髓灰质炎病毒P3/Leon/37及其减毒的萨宾疫苗衍生物P3/Leon 12a1b的基因组完整核苷酸序列比较。
Proc Natl Acad Sci U S A. 1984 Mar;81(5):1539-43. doi: 10.1073/pnas.81.5.1539.
5
The nucleotide sequence of poliovirus type 3 leon 12 a1b: comparison with poliovirus type 1.脊髓灰质炎病毒3型leon 12 a1b的核苷酸序列：与脊髓灰质炎病毒1型的比较。
Nucleic Acids Res. 1983 Aug 25;11(16):5629-43. doi: 10.1093/nar/11.16.5629.
6
Poliovirus type 3: molecular cloning of the genome and nucleotide sequence of the region encoding the protease and polymerase proteins.3型脊髓灰质炎病毒：基因组的分子克隆以及编码蛋白酶和聚合酶蛋白区域的核苷酸序列
Nucleic Acids Res. 1983 Mar 11;11(5):1267-81. doi: 10.1093/nar/11.5.1267.
7
Comparison of antibody responses and virus shedding following administration of trivalent oral poliomyelitis vaccines prepared either in monkey or human diploid cell substrates.在分别以猴肾细胞或人二倍体细胞为基质制备的三价口服脊髓灰质炎疫苗接种后，抗体反应和病毒排出情况的比较。
J Hyg (Lond). 1980 Feb;84(1):17-28. doi: 10.1017/s0022172400026474.
8
Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine.减毒活疫苗萨宾3型口服脊髓灰质炎病毒的神经毒力回复
Nucleic Acids Res. 1984 Oct 25;12(20):7787-92. doi: 10.1093/nar/12.20.7787.
9
Polio immunization policy in the United States: a new challenge for a new generation.美国的脊髓灰质炎免疫政策：新一代面临的新挑战。
Am J Public Health. 1988 Mar;78(3):296-300. doi: 10.2105/ajph.78.3.296.
10
Smallpox ten years gone: what next?天花已消除十年：接下来会怎样？
Br Med J (Clin Res Ed). 1987 Oct 24;295(6605):1013-4. doi: 10.1136/bmj.295.6605.1013.
本文引用的文献
1
Antigenic analysis of polioviruses by kinetic studies of serum neutralization.通过血清中和动力学研究对脊髓灰质炎病毒进行抗原分析。
Virology. 1959 Jan;7(1):45-58. doi: 10.1016/0042-6822(59)90176-x.
2
Genetic marker studies of poliovirus. I. Natural variation.脊髓灰质炎病毒的基因标记研究。I. 自然变异。
J Hyg (Lond). 1967 Mar;65(1):67-76. doi: 10.1017/s002217240004554x.
3
A survey of enteroviruses and adenoviruses in the faeces of normal children aged 0-4 years. A report of the Public Health Laboratory Service and the Society of Medical Officers of Health.0-4岁正常儿童粪便中肠道病毒和腺病毒的调查。公共卫生实验室服务处和卫生医疗官员协会的报告。
J Hyg (Lond). 1965 Dec;63(4):441-55. doi: 10.1017/s0022172400045344.
Zotero 插件